Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Angeion AngePass 4040

This article was originally published in The Gray Sheet

Executive Summary

Angeion AngePass 4040: Synthelabo subsidiary Ela plans to commence European sales of the 7.5 French single-pass lead in early 1998 after regulatory approval is granted for Angeion's and Ela's proposed 50-50 joint venture ("The Gray Sheet" Oct. 6, In Brief). Angeion reports Nov. 24 that it gained a CE Mark for the 4040 model series. Available in three lengths, the 4040 series "offers a tined passive fixation tip and is placed in the apex of the right ventricle," the firm says. The lead is designed for use with Angeion's Small Cap and Tuned biphastic waveform features, which are incorporated in the firm's Sentinel implantable cardioverter defibrillator and the 2020 ICD series, for which a premarket approval application and an investigational device exemption are pending at FDA, respectively...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel